N
CAI

Nuveen’s Caris Life Sciences CAI Stock Holding History

Nuveen’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.9M Buy
663,578
+641,165
+2,861% +$14M ﹤0.01% 1450
2025
Q4 		$605K Hold
22,413
– – ﹤0.01% 2804
2025
Q3 		$678K Buy
+22,413
New +$715K ﹤0.01% 2788

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Nuveen's CAI Position: Q1 2026 in Review

Nuveen increased its Caris Life Sciences (CAI) stake by 2,861% in Q1 2026, buying an estimated $14M and bringing the position to 663,578 shares worth $11.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1450.

Nuveen first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Nuveen held 663,578 shares of Caris Life Sciences worth $11.9M as of Q1 2026.
  • Nuveen bought 641,165 Caris Life Sciences shares in Q1 2026, an estimated $14M.
  • Caris Life Sciences made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #1450 holding.
  • Nuveen first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.